SV2A and major depressive disorder: The advent of a radioligand for the synaptic vesicle protein-2A (SV2A) enabled the first in vivo descriptions of reductions in synaptic density in MDD patients with and without PTSD comorbidity who expressed moderate-to-severe symptoms [83].